Literature DB >> 7396576

Clinical spectrum of pulmonary hamartomas.

T L Fudge, J L Ochsner, N L Mills.   

Abstract

Pulmonary hamartomas are tumors that occur in the parenchyma or the bronchi. Through the lesions themselves are benign, they may be associated with malignant neoplasms or they may cause obstruction of the bronchi because of their location. Pulmonary hamartomas were resected in 29 patients at the Ochsner Medical Institutions during a 30-year period. Of these patients, 6 had symptoms related to concomitant malignancy and 3 had symptoms resulting from obstruction of the bronchi by the hamartoma. Surgical treatment ranged from enucleation to pneumonectomy. One patient died in the hospital of extensive bronchogenic carcinoma. In 2 others, carcinoma of the lung developed within twelve months after resection of a hamartoma. In this group of patients, 20% had concomitant or subsequent pulmonary lesions. Ten percent of the hamartomas were located in the bronchi, resulting in bronchial obstruction. A surgical approach is indicated for lesions that appear to be pulmonary hamartomas on roentgenograms.

Entities:  

Mesh:

Year:  1980        PMID: 7396576     DOI: 10.1016/s0003-4975(10)61199-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Surgical treatment and outcome of pulmonary hamartoma: a retrospective study of 20-year experience.

Authors:  Wei Guo; Yun-Ping Zhao; Yao-Guang Jiang; Ru-Wen Wang; Zheng Ma
Journal:  J Exp Clin Cancer Res       Date:  2008-05-31

2.  Pulmonary Hamartoma Associated With Lung Cancer (PHALC Study): Results of a Multicenter Study.

Authors:  Alfonso Fiorelli; Antonio D'Andrilli; Annalisa Carlucci; Giovanni Vicidomini; Giacomo Argento; Beatrice Trabalza Marinucci; Francesco Ardissone; Roberta Rapanà; Simona Sobrero; Paolo Carbognani; Luigi Ventura; Giovanni Bocchialini; Mark Ragusa; Valentina Tassi; Francesco Sollitto; Domenico Loizzi; Nicoletta Pia Ardò; Marco Anile; Francesco Puma; Erino Angelo Rendina; Federico Venuta; Nicola Serra; Mario Santini
Journal:  Lung       Date:  2021-07-24       Impact factor: 2.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.